Research Analysts Issue Forecasts for IONS Q1 Earnings

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) - William Blair issued their Q1 2026 earnings per share estimates for shares of Ionis Pharmaceuticals in a report released on Wednesday, February 19th. William Blair analyst M. Minter expects that the company will post earnings per share of ($1.17) for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Ionis Pharmaceuticals' current full-year earnings is ($3.50) per share. William Blair also issued estimates for Ionis Pharmaceuticals' Q2 2026 earnings at ($1.07) EPS, Q3 2026 earnings at ($0.89) EPS and Q4 2026 earnings at ($0.85) EPS.

Ionis Pharmaceuticals (NASDAQ:IONS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($0.66) earnings per share for the quarter, beating analysts' consensus estimates of ($1.12) by $0.46. Ionis Pharmaceuticals had a negative return on equity of 100.05% and a negative net margin of 64.25%. The company had revenue of $227.00 million for the quarter, compared to analyst estimates of $140.97 million. During the same quarter last year, the firm posted $0.12 EPS. The firm's revenue for the quarter was down 30.2% on a year-over-year basis.

IONS has been the topic of a number of other reports. BMO Capital Markets lowered their target price on Ionis Pharmaceuticals from $60.00 to $45.00 and set a "market perform" rating on the stock in a report on Thursday, February 20th. Piper Sandler lowered their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Wells Fargo & Company cut their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an "overweight" rating for the company in a research note on Thursday, November 7th. Citigroup reduced their price objective on Ionis Pharmaceuticals from $67.00 to $64.00 and set a "buy" rating on the stock in a research note on Thursday, February 20th. Finally, StockNews.com lowered shares of Ionis Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, November 12th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Ionis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $60.00.

Remove Ads

Ionis Pharmaceuticals Price Performance

Ionis Pharmaceuticals stock traded down $0.41 during midday trading on Monday, reaching $31.35. 840,634 shares of the company were exchanged, compared to its average volume of 1,661,325. The company has a market capitalization of $4.98 billion, a price-to-earnings ratio of -10.31 and a beta of 0.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 8.82 and a current ratio of 8.47. The firm's 50-day simple moving average is $33.32 and its 200-day simple moving average is $37.98. Ionis Pharmaceuticals has a 1 year low of $30.23 and a 1 year high of $52.34.

Insider Activity at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, EVP Patrick R. O'neil sold 6,165 shares of the business's stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $31.62, for a total transaction of $194,937.30. Following the sale, the executive vice president now directly owns 57,452 shares in the company, valued at approximately $1,816,632.24. The trade was a 9.69 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Brett P. Monia sold 38,843 shares of the firm's stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $31.65, for a total transaction of $1,229,380.95. Following the completion of the transaction, the chief executive officer now owns 180,683 shares in the company, valued at $5,718,616.95. The trade was a 17.69 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 111,816 shares of company stock worth $3,603,914. 2.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Signaturefd LLC lifted its stake in Ionis Pharmaceuticals by 160.0% in the 4th quarter. Signaturefd LLC now owns 949 shares of the company's stock valued at $33,000 after purchasing an additional 584 shares during the last quarter. Huntington National Bank boosted its position in shares of Ionis Pharmaceuticals by 193.5% during the 4th quarter. Huntington National Bank now owns 951 shares of the company's stock valued at $33,000 after acquiring an additional 627 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in Ionis Pharmaceuticals by 183.8% during the 4th quarter. Lindbrook Capital LLC now owns 1,036 shares of the company's stock valued at $36,000 after acquiring an additional 671 shares during the period. Capital Performance Advisors LLP bought a new position in Ionis Pharmaceuticals in the third quarter worth about $40,000. Finally, Prospera Private Wealth LLC purchased a new stake in Ionis Pharmaceuticals during the 3rd quarter valued at about $42,000. Institutional investors and hedge funds own 93.86% of the company's stock.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.